Phase 2 data show significant reductions in nausea and vomiting that can cause patients to discontinue GLP-1s.

The mean systolic blood pressure (SBP) at baseline for Black and White patients not taking antihypertensive medication was 130.7 and 124.2 mm Hg, respectively. For those taking the drugs, mean SBP was ...

Q3 2025 Earnings Call November 12, 2025 8:00 AM ESTCompany ParticipantsHeather Hunter - Senior VP & COOMark Strobeck ...

LivaNova (Nasdaq: LIVN) today announced its new strategic roadmap and long-range financial plan at its 2025 Investor Day.

University of Auckland researchers report that an 8-week, twice-weekly LSD microdosing regimen for major depressive disorder ...

In a small, short duration trial (12 weeks), a new medication called DR10624 reduced triglyceride levels in most patients ...

An ultra-long-acting GLP-1 was tied to weight loss of up to 12.5% at 28 weeks among adults with overweight or obesity with no ...

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap and long-range financial plan.

WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...

Over the course of the patient's treatment, there were opportunities to recognize the error and prevent the patient's catastrophic results.

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

A new study undertaken by the Medical Research Institute of New Zealand (MRINZ) shows that adults with asthma can safely simplify their treatment, reduce overall steroid exposure and improve asthma ...